In this review:
Adjuvant sorafenib for RCC at intermediate or high risk of relapse
Effect of antacids on sunitinib efficacy in metastatic RCC
Prior TKI and antibiotic use: distinct gut microbiota ‘guilds’ in RCC
Immune checkpoint inhibitor efficacy and genomic alterations according to BMI in advanced RCC
TKI induction then nivolumab vs. TKI continuation in RCC
Tailored immunotherapy approach with nivolumab in advanced RCC
Nivolumab before and after cytoreductive nephrectomy in metastatic RCC
Telaglenastat + everolimus in advanced/metastatic RCC
PT2977 (an oral HIF-2α inhibitor) in advanced RCC
X4P-001 (an oral CXCR4 inhibitor) + axitinib in advanced RCC
Please login below to download this issue (PDF)